These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15585171)

  • 1. Exploiting death receptor signaling pathways for tumor therapy.
    Fulda S; Debatin KM
    Biochim Biophys Acta; 2004 Dec; 1705(1):27-41. PubMed ID: 15585171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling through death receptors in cancer therapy.
    Fulda S; Debatin KM
    Curr Opin Pharmacol; 2004 Aug; 4(4):327-32. PubMed ID: 15251124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death receptors in chemotherapy and cancer.
    Debatin KM; Krammer PH
    Oncogene; 2004 Apr; 23(16):2950-66. PubMed ID: 15077156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis signaling in tumor therapy.
    Fulda S; Debatin KM
    Ann N Y Acad Sci; 2004 Dec; 1028():150-6. PubMed ID: 15650241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Death receptor signaling in cancer therapy.
    Fulda S; Debatin KM
    Curr Med Chem Anticancer Agents; 2003 Jul; 3(4):253-62. PubMed ID: 12769771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of TRAIL signaling for cancer therapy.
    Fulda S; Debatin KM
    Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Death receptor signaling and its function in the immune system.
    Fas SC; Fritzsching B; Suri-Payer E; Krammer PH
    Curr Dir Autoimmun; 2006; 9():1-17. PubMed ID: 16394652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines.
    Dechant MJ; Fellenberg J; Scheuerpflug CG; Ewerbeck V; Debatin KM
    Int J Cancer; 2004 May; 109(5):661-7. PubMed ID: 14999771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Messengers of cell death: apoptotic signaling in health and disease.
    Rossi D; Gaidano G
    Haematologica; 2003 Feb; 88(2):212-8. PubMed ID: 12604411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond apoptosis: nonapoptotic cell death in physiology and disease.
    Hetz CA; Torres V; Quest AF
    Biochem Cell Biol; 2005 Oct; 83(5):579-88. PubMed ID: 16234846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy.
    Fulda S; Debatin KM
    Oncogene; 2006 Aug; 25(34):4798-811. PubMed ID: 16892092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.
    Cascino I; Papoff G; De Maria R; Testi R; Ruberti G
    J Immunol; 1996 Jan; 156(1):13-7. PubMed ID: 8598453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase inhibitors induce a switch from apoptotic to proinflammatory signaling in CD95-stimulated T lymphocytes.
    Scheller C; Sopper S; Ehrhardt C; Flory E; Chen P; Koutsilieri E; Ludwig S; ter Meulen V; Jassoy C
    Eur J Immunol; 2002 Sep; 32(9):2471-80. PubMed ID: 12207331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review).
    Gupta S
    Int J Oncol; 2003 Jan; 22(1):15-20. PubMed ID: 12469180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
    van Geelen CM; de Vries EG; Le TK; van Weeghel RP; de Jong S
    Br J Cancer; 2003 Jul; 89(2):363-73. PubMed ID: 12865931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL and apoptosis induction by TNF-family death receptors.
    Wang S; El-Deiry WS
    Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
    Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
    Schimmer AD; Thomas MP; Hurren R; Gronda M; Pellecchia M; Pond GR; Konopleva M; Gurfinkel D; Mawji IA; Brown E; Reed JC
    Cancer Res; 2006 Feb; 66(4):2367-75. PubMed ID: 16489043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of tumor necrosis factor receptor and Fas signaling pathways by transcriptional profiling.
    Manos EJ; Jones DA
    Cancer Res; 2001 Jan; 61(2):433-8. PubMed ID: 11212226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does "death receptor" signaling play a role in tumorigenesis and cancer therapy?
    Villunger A; Strasser A
    Oncol Res; 1998; 10(11-12):541-50. PubMed ID: 10367935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.